Is Pretreatment With P2Y12 Inhibitors in Non-ST-Segment-Elevation Acute Coronary Syndrome Clinically Justified? Pretreatment With P2Y12 Inhibitors in Non-ST-Segment-Elevation Acute Coronary Syndrome Is Clinically Justified Response

被引：0
|
作者：
Collet, Jean-Philippe
Silvain, Johanne
Bellemain-Appaix, Anne
Montalescot, Gilles
机构：
来源：
CIRCULATION | 2014年 / 130卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1903 / 1903
页数：1
相关论文
共 50 条
  • [31] Pre-Treatment With Oral P2Y12 Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndromes Does One Size Fit All?
    Ferreiro, Jose Luis
    JACC-CARDIOVASCULAR INTERVENTIONS, 2020, 13 (08) : 918 - 920
  • [32] Pretreatment With P2Y12 Inhibitors in ST-Segment Elevation Myocardial Infarction Insights From the Bern-PCI Registry
    Rohla, Miklos
    Ye, Shirley Xinyu
    Shibutani, Hiroki
    Bruno, Jolie
    Otsuka, Tatsuhiko
    Haner, Jonas D.
    Baer, Sarah
    Temperli, Fabrice
    Kavaliauskaite, Raminta
    Lanz, Jonas
    Stortecky, Stefan
    Praz, Fabien
    Hunziker, Lukas
    Pilgrim, Thomas
    Siontis, George CM.
    Losdat, Sylvain
    Windecker, Stephan
    Raeber, Lorenz
    JACC-CARDIOVASCULAR INTERVENTIONS, 2024, 17 (01) : 17 - 28
  • [33] Things We Do for No Reason™: Routine pretreatment with a P2Y12 receptor inhibitor before invasive coronary angiography for patients with a non-ST elevation acute coronary syndrome
    O'Malley, Kevin
    Hwang, Yoseob Joseph
    Trost, Jeffrey
    Feldman, Leonard
    JOURNAL OF HOSPITAL MEDICINE, 2023, 18 (02) : 177 - 180
  • [34] Prognostic implication of unrecognized myocardial infarction in patients with non-ST-segment-elevation acute coronary syndrome
    Sayama, K.
    Hoshino, M.
    Kanaji, Y.
    Sugiyama, T.
    Misawa, T.
    Hada, M.
    Nagamine, T.
    Nogami, K.
    Teng, Y.
    Ueno, H.
    Matsuda, K.
    Yonetsu, T.
    Kakuta, T.
    EUROPEAN HEART JOURNAL, 2022, 43 : 287 - 287
  • [35] MARKED DIFFERENCES IN THE PHARMACODYNAMICS OF MODERN P2Y12 INHIBITORS IN PATIENTS UNDERGOING TREATMENT FOR ST SEGMENT ELEVATION MI (STEMI) AND NON ST SEGMENT ELEVATION MI (NSTEMI)
    Amoah, Vincent
    Khan, Nazish
    Smallwood, Andrew
    Wrigley, Ben
    Martins, Joe
    Khogali, Saib
    Munir, Shahzad
    Alan, Nevill
    Cotton, James
    HEART, 2016, 102 : A77 - A78
  • [36] Impact of Ticagrelor Versus Clopidogrel on Coronary Microvascular Function After Non-ST-Segment-Elevation Acute Coronary Syndrome
    Xu, James
    Lo, Sidney
    Mussap, Christian J.
    French, John K.
    Rajaratnam, Rohan
    Kadappu, Krishna
    Premawardhana, Upul
    Nguyen, Phong
    Juergens, Craig P.
    Leung, Dominic Y.
    CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2022, 15 (04) : E011419
  • [37] Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non ST-Elevation Acute Coronary Syndrome
    Bavishi, Chirag
    Panwar, Sadik
    Messerli, Franz H.
    Bangalore, Sripal
    AMERICAN JOURNAL OF CARDIOLOGY, 2015, 116 (05): : 809 - 817
  • [38] Pretreatment with P2Y12 inhibitors in ST-elevation myocardial infarction: Should we keep doing it?
    Proenca, Goncalo
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2020, 39 (10) : 563 - 564
  • [39] The Role of Direct-Acting P2Y12 Inhibitors in Acute Coronary Syndrome
    Buryakina, T. A.
    Zateyshchikov, D. A.
    KARDIOLOGIYA, 2012, 52 (04) : 74 - 79
  • [40] P2Y12 Receptor Inhibitors: Integrating Ticagrelor into the Management of Acute Coronary Syndrome
    Crouch, Michael A.
    Colucci, Vince J.
    Howard, Patricia A.
    Spinler, Sarah A.
    ANNALS OF PHARMACOTHERAPY, 2011, 45 (09) : 1151 - 1156
12345